Event

BioAegis sponsored webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases will delve beneath the surface of this rapidly growing field of auto-inflammatory and hyper-inflammatory diseases. It will explore what we know and will need to know moving forward, in particular: How these diseases of the innate immune …

May 23, 2023: Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases Read More »

BioAegis co-founders were selected to present at the upcoming MACRO Trends Investors Conference in Belgium. The presentation, “Conquering Pneumonia and Systemic Inflammation,” will highlight BioAegis’ novel, host-directed treatment. About MACRO Trends MACRO Trends is a Dutch Investment advisory firm centered around a regularly published magazine edited by Brecht Arnaert, a monetary expert at the Rey …

November 12, 2021: Belgium MACRO Trends Investors Conference Read More »

Virtual Conference: Navigating Unprecedented Global Uncertainty Tuesday, October 6th and Wednesday, October 7th 2020 Developed with J.P. Morgan and Johnson & Johnson Innovation, BioNJ’s Virtual Two-Day BioPartnering Conference will bring together life sciences professionals from the Northeast and beyond. Last year’s Conference convened attendees representing 17 states and 5 countries. Come ready to meet investors, industry executives and partnering professionals; …

October 6-7, 2020: BioNJ’s 10th Annual BioPartnering Conference Read More »

The leadership team of BioAegis Therapeutics will share their experiences this year as they reframed their strategy to address the COVID-19 threat to their employees and hustled to initiate a COVID-19 clinical trial for severe COVID-19 patients. When: Thursday, August 20, 2020 12:00 p.m. – 1:00 p.m. EDT Where: Online (GoToWebinar) Contact: WIB-Metro New York …

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience Read More »

BioAegis has been selected as a featured company in the upcoming BioNJ COVID-19 Rapid Fire Research Showcase.  Our Chief Executive Officer and Co-founder, Dr. Susan Levinson, will present our goundbreaking recombinant human plasma gelsolin (rhu-pGSN) therapy. WHEN:    Friday, June 5, 2020, 9:00 a.m. – 10:00 a.m. Register Now